Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Center, Single-Dose, 2-Way Crossover, Randomized Food-Effect and Non-Randomized Gender- and Age- Effect Pharmacokinetic Study of SUVN-D4010 Orally Administered in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Single-Center, Single-Dose, 2-Way Crossover, Randomized Food-Effect and Non-Randomized Gender- and Age- Effect Pharmacokinetic Study of SUVN-D4010 Orally Administered in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Usmarapride (Primary)
  • Indications Cognition disorders
  • Focus First in man; Pharmacokinetics
  • Sponsors Suven Life Sciences

    • Most Recent Events

    • 31 Mar 2021 Results of early investigations on the safety, tolerability, and pharmacokinetics of SUVN D4010 in healthy young adult and elderly subjects published in the Clinical Drug Investigation
    • 21 Sep 2017 Status changed from recruiting to completed.
    • 20 Jul 2017 Results of two phase I studies including this study presented at the Alzheimer's Association International Conference 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top